A compound derived from traditional Chinese toad venom may strike melanoma where it hurts most. New research published in Cancer Reports shows that bufalin, a cardiotonic steroid long used in Chinese medicine, suppresses the growth, migration and invasion of malignant melanoma cells while simultaneously choking off the angiogenic behavior of vascular endothelial cells. The unifying mechanism, according to the study, is a single molecular event: a marked reduction in phosphorylated AKT, the activated form of a master signaling kinase that tumor cells and growing blood vessels both depend on. Because alterations in the PI3K/AKT pathway occur in up to 70 percent of melanoma cases and are linked to disease progression, the finding offers a mechanistic rationale for repurposing an ancient remedy against one of the most lethal skin cancers.
Malignant melanoma arises from melanocytes, the pigment-producing cells of the skin, and its incidence and mortality have been climbing steadily. Advanced disease carries a particularly grim outlook: melanomas are notoriously insensitive to conventional chemotherapy and radiotherapy, leaving patients with a five-year survival rate of roughly 32 to 52 percent. Targeted therapies against BRAF-mutant tumors and modern immunotherapies have improved outcomes, but resistance is common, and AKT signaling remains frequently activated in both BRAF-mutant and BRAF-wild-type melanomas. That makes an agent capable of damping AKT phosphorylation attractive precisely because it should not care which side of the BRAF divide a tumor sits on.
Bufalin itself is no newcomer to the pharmacopoeia. Extracted from the venom of toads used in the traditional medicine known as Chan Su, the steroid has been deployed clinically in China to treat tumor recurrence and metastasis, where it reportedly reduces the side effects of radiotherapy and chemotherapy while improving quality of life. Laboratory studies have already documented anti-tumor activity in lung, colorectal, breast and liver cancers. But in melanoma, prior work had focused mainly on apoptosis induction through caspase and mitochondrial pathways or on identifying individual binding targets. What remained unresolved was whether bufalin converges on p-AKT as a central node coordinating both cell death and cell cycle arrest — and whether this holds independent of BRAF status.
The new study set out to answer that question with a battery of assays in two BRAF-mutant melanoma cell lines, A375 and A2058, alongside human umbilical vein endothelial cells, the standard workhorse for modeling angiogenesis. In viability assays, bufalin inhibited melanoma cell growth in a dose- and time-dependent manner, with half-maximal inhibitory concentrations of 20 and 17.5 nanomolar at 24 and 48 hours in A375 cells, and 60 and 30 nanomolar in A2058 cells. Colony formation, a proxy for long-term proliferative capacity, fell significantly as bufalin concentrations rose. These are strikingly low concentrations — tens of nanomoles — underscoring the potency of the molecule.
Flow cytometry revealed how the growth suppression was achieved. Untreated cultures showed apoptotic fractions below 5 percent, but bufalin pushed apoptosis to 10 to 20 percent at 10 nanomolar and 30 to 40 percent at 20 nanomolar. At the same time, the proportion of cells trapped in the G2/M phase of the cell cycle rose markedly, indicating that bufalin does not merely kill cells but also halts their division machinery. The team then probed metastatic behavior: wound healing assays showed widened scratches after 12 hours of treatment, and transwell experiments demonstrated that fewer melanoma cells migrated through porous membranes or invaded through a Matrigel matrix at concentrations of 5 and 10 nanomolar. Migration and invasion, the twin engines of metastasis, were both throttled.
Crucially, the compound also targeted the tumor’s blood supply. In endothelial cells, bufalin inhibited proliferation with IC50 values of 40 nanomolar at 24 hours and 20 nanomolar at 48 hours, reduced colony formation, slowed wound closure, and curtailed migration through transwell chambers. Most dramatically, in Matrigel tube formation assays, the dendritic vascular networks that endothelial cells normally weave were fewer, fragmented and structurally destroyed at 10 nanomolar. Since tumors co-opt angiogenesis to secure nutrients and oxygen as they grow and spread, an agent that simultaneously attacks tumor cells and the endothelial cells feeding them addresses both sides of the tumor-vascular equation.
To identify the signaling pathway behind these effects, the researchers turned to network pharmacology, an interdisciplinary approach that fuses medicine, pharmacology and bioinformatics to map how a multi-target molecule engages a biological system. Cross-referencing predicted bufalin targets from the PharmMapper database with melanoma genes from MalaCards and angiogenesis genes from GENECLIP yielded 57 key shared targets. Gene Ontology analysis pointed to stimulus response and biological regulation as dominant biological processes, while Kyoto Encyclopedia of Genes and Genomes pathway enrichment ranked the PI3K-AKT pathway first among 20 candidate pathways. Protein-protein interaction network analysis identified MAPK, AKT1 and p53 as the most connected hub genes, with modular analysis again crowning PI3K-AKT as the most important signaling route.
Molecular docking then simulated how bufalin might engage AKT1 at the atomic level. The docking score of −3.956 suggested a favorable interaction, with the model showing bufalin forming a hydrogen bond with the 53rd asparagine residue of AKT1. Because docking is only a theoretical prediction, the team validated it experimentally. Western blotting showed that total PI3K and total AKT protein levels were essentially unchanged after bufalin treatment in both melanoma and endothelial cells, but phosphorylated AKT — detected at the Ser473 regulatory site — dropped significantly. The decisive test came from rescue experiments using SC-79, a small-molecule activator that drives AKT phosphorylation. Adding SC-79 restored p-AKT levels, and bufalin reversed that increase, demonstrating that the compound acts upstream to suppress AKT activation rather than merely masking its downstream readouts.
The in vivo evidence followed. In xenograft models, A375 melanoma cells were implanted subcutaneously into nude mice, and once tumors reached roughly 100 cubic millimeters, animals received daily intraperitoneal bufalin at 1.5 milligrams per kilogram for 12 days. Tumors in treated mice grew more slowly and ended the experiment significantly smaller and lighter than vehicle controls. Immunohistochemistry on excised tumor sections confirmed the mechanism in tissue: staining for phosphorylated AKT and for Ki-67, a canonical proliferation marker, was markedly reduced after treatment. Notably, the mice showed no obvious loss of body weight during the treatment period, suggesting the antitumor effects came without apparent systemic toxicity under the experimental conditions.
The authors argue that these results establish p-AKT as the key mechanistic node for bufalin’s action in melanoma, and the clinical implications are twofold. First, because p-AKT downregulation appears sufficient to trigger anti-tumor effects regardless of BRAF mutation status, bufalin could in principle work against a broad range of melanomas, including tumors resistant to BRAF and MEK inhibitors. Second, as a natural compound with an existing history of use in traditional Chinese medicine, bufalin could be repurposed as an adjunct therapy to enhance existing treatments or to overcome resistance. Earlier studies support this framing: bufalin has been shown to suppress hepatocellular carcinoma invasion via PI3K/AKT/HIF-1 signaling, to induce lung cancer apoptosis through PI3K/AKT inhibition, to reverse cisplatin resistance in gastric cancer by blocking AKT activation, and to enhance sorafenib’s anti-angiogenic effect through the PI3K-AKT-VEGF axis. The authors caution that much remains to be done: future work should test bufalin in combination with targeted agents and immunotherapies in preclinical models, and rigorously evaluate its safety and pharmacokinetics in melanoma patients. But the conceptual shift is clear — a single upstream event, the silencing of AKT phosphorylation, may be enough to orchestrate apoptosis, cell cycle arrest and angiogenesis blockade all at once, offering a new framework for developing toad venom’s most potent secret into a modern anti-melanoma drug.
Subject of Research: Bufalin’s inhibition of melanoma progression and endothelial angiogenesis through suppression of AKT phosphorylation
Article Title: Bufalin Inhibits Melanoma Progression and Endothelial Angiogenic Phenotypes via AKT Signaling
Article References: Zhao, X. X., Li, M. X., & Qu, J. X. (2026). Bufalin Inhibits Melanoma Progression and Endothelial Angiogenic Phenotypes via AKT Signaling. Cancer Reports, 9(9), Article e70674. https://doi.org/10.1002/cnr2.70674
Image Credits: AI Generated
DOI: 10.1002/cnr2.70674
Keywords: bufalin, melanoma, AKT signaling, PI3K-AKT pathway, angiogenesis, toad venom, apoptosis, cell cycle arrest, network pharmacology, molecular docking, xenograft model, BRAF mutation
Cite Scienmag News
APA
MLA
Chicago
Nathaniel Bowman. (September 26, 2026). Toad Venom Compound Bufalin Blocks Melanoma Growth by Switching Off AKT Signaling. Scienmag. https://scienmag.com/toad-venom-compound-bufalin-blocks-melanoma-growth-by-switching-off-akt-signaling/
Nathaniel Bowman. “Toad Venom Compound Bufalin Blocks Melanoma Growth by Switching Off AKT Signaling.” Scienmag, 26 September 2026, https://scienmag.com/toad-venom-compound-bufalin-blocks-melanoma-growth-by-switching-off-akt-signaling/. Accessed 26 September 2026.
Nathaniel Bowman. “Toad Venom Compound Bufalin Blocks Melanoma Growth by Switching Off AKT Signaling.” Scienmag. September 26, 2026. https://scienmag.com/toad-venom-compound-bufalin-blocks-melanoma-growth-by-switching-off-akt-signaling/
Copy citation
Download RIS
Tags: AKT signalingAKT signaling pathway inhibitionangiogenesisapoptosisBRAF mutationbufalincell cycle arrestmelanomamelanoma cell migration and invasionmelanoma growth suppressionmolecular dockingmolecular mechanisms of melanoma progressionnatural compounds in cancer therapynetwork pharmacologyPI3K/AKT pathwayPI3K/AKT pathway in melanomarepurposing bufalin for skin cancer therapyresistance to melanoma therapiestargeting AKT in melanomatoad venomToad venom compound bufalintraditional Chinese medicine in cancer treatmenttumor angiogenesis inhibitionxenograft model
